原国泰基金经理姜英管3只产品任期均亏损，转行担任罗欣药业董秘，前任董秘年薪84万

Core Viewpoint - The appointment of Jiang Ying as the new Secretary of the Board at Luoxin Pharmaceutical marks a trend of fund managers transitioning into corporate governance roles, highlighting the increasing intersection between investment management and corporate leadership [1]. Company Summary - Luoxin Pharmaceutical announced the resignation of its Secretary of the Board, Han Fengsheng, due to job relocation, and appointed Jiang Ying, a former fund manager, as the new Secretary [1]. - Jiang Ying has a strong educational background with dual degrees in Science and Economics from Peking University, a Master's in Management from Peking University, and a Master's in Finance from the University of Hong Kong [2]. - Jiang Ying has four years of experience managing public funds, overseeing three fund products, including Guotai Jinniu Innovation Growth Mixed Fund, Guotai Science and Technology Innovation Board Two-Year Open Mixed Fund, and Guotai Small and Medium Cap Growth Mixed Fund [3]. Fund Management Performance - The funds managed by Jiang Ying have shown poor performance during her tenure, with returns of -7.01% for Guotai Jinniu Innovation Growth, -12.48% for Guotai Science and Technology Innovation Board Two-Year Open, and -34.28% for Guotai Small and Medium Cap Growth [4]. - The peak management scale reached 2.59 billion yuan in Q1 2022, but it has since declined, with Jiang Ying set to leave her last fund on December 24, 2024, for personal reasons [4]. Compensation and Future Outlook - The previous Secretary of the Board, Han Fengsheng, had an annual salary of 845,700 yuan, raising questions about Jiang Ying's future performance and compensation [5].